

Discoveries for life / Découvertes pour la vie

CIHR Rare Disease Research Initiative Update

Étienne Richer Ph.D. – CIHR Institute of Genetics


February 28, 2024





CIHR Rare Disease Research Initiative

Part of the National Strategy for Drugs for Rare Diseases



Improving Diagnosis for Rare Disease Patients

Purpose

• To determine the **best pathway to diagnose RDs** by moving genomic testing towards the front end of the care pathway.

Specific Objectives

- Generate evidence to optimize the RD diagnosis pathway;
- Evaluate health outcomes associated with RDs via the 'genomics first' diagnosis pathway;
- Determine the economic impact to the health care system;
- Evaluate the socioeconomic and psychological impacts on patients and families; and
- Mobilize knowledge to facilitate the implementation, scale and spread of best practices for diagnosing RDs in Canada.

Intersections

Canadian Rare Disease Network, All for One, Pan Canadian Genomic Library, Silent Genomes
Project



Improving Health and Administrative Data and Monitoring for Rare Diseases

Purpose

• To support implementation research to **determine the prevalence**, **direct cost**, **and impact of RDs** in the Canadian health care system.

Specific Objectives

- Demonstrate the feasibility of tracking rare diseases and conducting prospective studies;
- Increase cross-jurisdictional collaboration and data sharing;
- Prospectively assess the impact of mortality, co-morbidities, health system usage, and total direct cost of rare diseases; and
- Facilitate the establishment of patient registries.

Intersections

CADTH and CIHI DRD strategy components, CADTH Real World Evidence activities

Bringing Rare Disease Gene Therapies to Clinical Trial Readiness

Purpose

 To bridge the current gap between model organisms/systems and clinical trials for rare disease drugs in Canada, ultimately increasing the capacity to bring gene therapies to clinic.

Specific Objectives

- Increase and advance the development of gene therapies for rare disease clinical trials in Canada;
- Generate evidence for first-in-human clinical trials, in part by working with Canada's biomanufacturing capacity (National Research Council of Canada) and health technology regulator (Health Canada); and,
- Increase capacity across the Canadian landscape to improve readiness of gene therapies for trials.

Intersections

• Biomanufacturing Strategy, Regulatory Modernization, Clinical Trials Fund

Pediatric Rare Disease Clinical Trials and Treatment Network

Purpose

• To create a Pediatric Rare Disease Clinical Network to **streamline RD clinical research across Canada and to facilitate collaboration** among researchers, people with lived and living experience, health care providers, industry, policy and regulatory bodies.

Specific Objectives

- Develop a platform to support pediatric rare disease clinical trials in Canada;
- Increase the capacity to perform rare disease clinical trials in Canada;
- Attract international clinical trials, increasing investments in Canada and providing earlier access to innovative therapies;
- Foster diversity and inclusion in and improve access to clinical trials;
- Implement processes to **acquire data** from clinical trials, real world registries, health economics evaluation, and post-marketing surveillance; and,
- Increase the number of new rare disease drug submissions in Canada.

Intersections

• Canadian Rare Disease Network, ERDERA, National Mirror Group...



Patient Partners Involvement In the RDRI

Informed the development of the scope and objectives of the initiative Ensured that there was appropriate inclusion in the funding opportunities Integrated as full partners in the applications Participated fully in the peer review process Will have a key role in all funded projects Will be central to all knowledge mobilization to increase the impacts

Patient Partnership at CIHR Institute of Genetics

Patient partnership in research is when researchers work together with people with lived experience of a health condition to do research.

The Institute of Genetics now uses the term "patient partnership" instead of "patient engagement" because we believe this term better reflects the value of patient contributions to research.



More Information on our activities!

- Training and resources
- Community of practice
- Patient partner committee
- Funding
- Featured research







Discoveries for life / Découvertes pour la vie